{"id":957502,"date":"2026-05-04T08:06:14","date_gmt":"2026-05-04T12:06:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/"},"modified":"2026-05-04T08:06:14","modified_gmt":"2026-05-04T12:06:14","slug":"lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/","title":{"rendered":"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, May  04, 2026  (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of <a href=\"http:\/\/www.vizz.com\" rel=\"nofollow\" target=\"_blank\">VIZZ\u00ae<\/a> (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights.<\/p>\n<p align=\"justify\">To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed\u00a0<a href=\"https:\/\/edge.media-server.com\/mmc\/p\/xym9k99k\/\" rel=\"nofollow\" target=\"_blank\">here<\/a>\u00a0and on the LENZ Therapeutics website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nTyAhgKfnN3CeLcXOuSJRCq8NmS7vAti0ytV7qgLlJzjWJBYqipNPQpeItB3P9_pfrMAAXUkwOVJxMWGPWIofw==\" rel=\"nofollow\" target=\"_blank\">www.LENZ-tx.com<\/a>\u00a0in the Investors &amp; Media section. A replay of the webcast will be available on the Company\u2019s website for 30 days following the event.<\/p>\n<p align=\"justify\">In addition, company management will host one-on-one meetings at the Bank of America Global Healthcare Conference on May 13\u201314, 2026, in Las Vegas, Nevada.<\/p>\n<p align=\"justify\">\n        <strong>About LENZ Therapeutics<\/strong><br \/>\n        <br \/>LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit <a href=\"http:\/\/www.VIZZ.com\" rel=\"nofollow\" target=\"_blank\">www.VIZZ.com<\/a> and <a href=\"http:\/\/www.LENZ-tx.com\" rel=\"nofollow\" target=\"_blank\">www.LENZ-tx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Dan Chevallard <br \/>LENZ Therapeutics<br \/><a href=\"mailto:IR@LENZ-Tx.com\" rel=\"nofollow\" target=\"_blank\">IR@LENZ-Tx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2M2MTZlZjQtNTc3Zi00MThjLTllZmYtOTdkMTUzZTI0ZDhjLTEyNzU1MzctMjAyNi0wNS0wNC1lbg==\/tiny\/LENZ-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed\u00a0here\u00a0and on the LENZ Therapeutics website at\u00a0www.LENZ-tx.com\u00a0in the Investors &amp; Media section. A replay of the webcast will be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957502","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed\u00a0here\u00a0and on the LENZ Therapeutics website at\u00a0www.LENZ-tx.com\u00a0in the Investors &amp; Media section. A replay of the webcast will be available &hellip; Continue reading &quot;LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T12:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference\",\"datePublished\":\"2026-05-04T12:06:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/\",\"name\":\"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=\",\"datePublished\":\"2026-05-04T12:06:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - Market Newsdesk","og_description":"SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed\u00a0here\u00a0and on the LENZ Therapeutics website at\u00a0www.LENZ-tx.com\u00a0in the Investors &amp; Media section. A replay of the webcast will be available &hellip; Continue reading \"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-04T12:06:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference","datePublished":"2026-05-04T12:06:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/","name":"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=","datePublished":"2026-05-04T12:06:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjA2MiM3NTgwMTY4IzIyNjM5ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957502"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957502\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}